ArticleScience translational medicine2019

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Christina Claus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.